<?xml version="1.0" encoding="UTF-8"?>
<p>Further analyses (i.e., determination of prognostic power, diagnostic performance, and druggability) were implemented by taking into account 50 DIPs specific to ccRCC, 29 DIPs specific to pRCC, and the top 50 DIPs having the most interactions specific to chRCC (
 <xref rid="jpm-11-00158-t001" ref-type="table">Table 1</xref>). We considered those DIPs as a cluster for each subtype and suggested them as potential systems biomarkers for the development of effective diagnosis, prognosis, and treatment strategies.
</p>
